Analyzing VistaGen Therapeutics (NASDAQ:VTGN) & Alvotech (NASDAQ:ALVO)

VistaGen Therapeutics (NASDAQ:VTGN) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares VistaGen Therapeutics and Alvotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Alvotech	4.74%	-11.92%	2.02%

Insider and Institutional Ownership

78.4% of VistaGen Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

VistaGen Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VistaGen Therapeutics and Alvotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1	4	0	0	1.80
Alvotech	2	2	2	0	2.00

VistaGen Therapeutics presently has a consensus target price of $0.95, suggesting a potential upside of 57.52%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 109.94%. Given Alvotech’s stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than VistaGen Therapeutics.

Earnings & Valuation

This table compares VistaGen Therapeutics and Alvotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$789,000.00	30.28	-$51.42 million	($1.89)	-0.32
Alvotech	$588.90 million	1.86	$27.92 million	$0.10	36.20

Alvotech has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Summary

Alvotech beats VistaGen Therapeutics on 10 of the 14 factors compared between the two stocks.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.